SCHEMBL3352990

SCHEMBL3352990

Nc1cnc(C(=O)OCc2ccccc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.57
TDP1 Q9NUW8 3/20 0.51
KMT2A Q03164 2/20 0.51
SLC6A2 P23975 1/20 0.51
SLC6A3 Q01959 1/20 0.51
LMNA P02545 3/20 0.49
TSHR P16473 2/20 0.48
ALDH1A1 P00352 4/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
MAOB P27338 1/20 0.47
ADORA2A P29274 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
P4HTM Q9NXG6 1/20 0.47
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1712317 0.96 POLB (0.54) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL20400819 0.82 TDP1 (0.51) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL3622336 0.82 POLB (0.57) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL15075637 0.82 POLB (0.85) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL24218219 0.81 POLB (0.57) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL24269953 0.79 MAPT (0.54) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL12094229 0.79 POLB (0.58) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL1712044 0.79 KMT2A (0.60) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL12091517 0.78 POLB (0.57) POLBTDP1KMT2ASLC6A2SLC6A3
SCHEMBL23397122 0.78 LMNA (0.58) POLBTDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3082867-B1 ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS INTERVET INT BV (NL) 2024-01-17 EP disclosed
EP-4306168-A2 ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS Intervet International B.V. (NL) 2024-01-17 EP disclosed
EP-4076447-B1 PARASITE CONTROL IN RUMINANTS INTERVET INT BV (NL) 2024-01-17 EP disclosed
EP-4153133-B1 INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF INTERVET INT BV (NL) 2023-11-08 EP disclosed
EP-3878281-B1 USE OF ISOXAZOLINE COMPOUNDS IN POULTRY INTERVET INT BV (NL) 2023-05-24 EP disclosed
EP-2833867-B2 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INT BV (NL) 2023-05-10 EP disclosed
WO-2022269042-A1 PALATABLE VETERINARY COMPOSITIONS INTERVET INTERNATIONAL B.V. (NL) 2022-12-29 WO disclosed
WO-2022258797-A1 TICK CONTROL METHODS INTERVET INTERNATIONAL B.V. (NL) 2022-12-15 WO disclosed
EP-4008329-A1 ISOXAZOLINE COMPOUNDS FOR USE IN TREATING DEMODICOSIS Intervet International B.V. (NL) 2022-06-08 EP disclosed
EP-2658542-B1 TOPICAL LOCALIZED ISOXAZOLINE FORMULATION INTERVET INT BV (NL) 2022-01-26 EP disclosed
US-20120225910-A1 Substituted Heteroaryls PFIZER INC. (US) 2012-09-06 US disclosed
US-20120225910-A1 Substituted Heteroaryls PFIZER INC. (US) 2012-09-06 US disclosed
US-20110230445-A1 Substituted Heteroaryls PFIZER INC 2011-09-22 US disclosed
US-20110230445-A1 Substituted Heteroaryls PFIZER INC 2011-09-22 US disclosed
US-7977367-B2 Substituted imidazole propanamide glucokinase activators PFIZER INC (US) 2011-07-12 US disclosed
US-7977367-B2 Substituted imidazole propanamide glucokinase activators PFIZER INC (US) 2011-07-12 US disclosed
WO-2010029461-A1 HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-03-18 WO disclosed
WO-2010029461-A1 HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-03-18 WO disclosed
US-20100063063-A1 Substituted Heteroaryls PFIZER INC 2010-03-11 US disclosed
US-20100063063-A1 Substituted Heteroaryls PFIZER INC 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225910-A1 Substituted Heteroaryls GCKR, GCK, GALK1 POLB 3502/4885TDP1 2782/4885KMT2A 2365/4885
US-20110230445-A1 Substituted Heteroaryls GCKR, GCK, GALK1 POLB 3541/4885TDP1 2754/4885KMT2A 2175/4885
US-20100063063-A1 Substituted Heteroaryls GCKR, GCK, GALK1 POLB 3541/4885TDP1 2754/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.